Changing Faces: Board of Directors, January 2026
January was a relatively quiet month for Board news, but there were some notable moves here and there.
Newsletters and Deep Dive digital magazine
January was a relatively quiet month for Board news, but there were some notable moves here and there.
Volunteers with schizophrenia, bipolar, and depression will take part in an NHS study that will use genetic and health data to find new therapies.
Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.
Armed with new data, Compass wants to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression.
Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.
Editor's Picks
Newsletters and Deep Dive
digital magazine